Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
暂无分享,去创建一个
D. Lake | C. Hudis | L. Norton | T. Traina | A. Seidman | S. Patil | T. Gilewski | G. D’Andrea | N. Sklarin | S. Sugarman | M. Fornier | P. Drullinsky | T. Troso-Sandoval | N. Mills | C. Wasserheit-Lieblich | J. Yuan | Deena Atieh-Graham | H. Patel | Carolyn Wasserheit-Lieblich
[1] D. Lake,et al. A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma , 2009, Breast Cancer Research and Treatment.
[2] D. West,et al. Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT) , 2008 .
[3] M. Provencio,et al. R‐CHOP‐14 in patients with diffuse large B‐cell lymphoma younger than 70 years: a multicentre, prospective study , 2008, Hematological oncology.
[4] C. Hudis,et al. Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data. , 2007, Clinical breast cancer.
[5] J. Baselga,et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis , 2007 .
[6] D. Lake,et al. Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer , 2007, Clinical Cancer Research.
[7] B. Coiffier,et al. State-of-the-art therapeutics: diffuse large B-cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Zelenetz,et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy , 2005, Leukemia & lymphoma.
[9] G. Bonadonna,et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study , 2005, BMJ : British Medical Journal.
[10] D. Wickerham,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Huvos,et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Bonetti,et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF , 2002, British Journal of Cancer.
[14] C. Hudis,et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] C. Hudis,et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Goldhirsch,et al. Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer , 1998 .
[17] G. Bonadonna,et al. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.
[18] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[19] J. Boyages,et al. Intravenous or oral adjuvant CMF for node-positive breast cancer. , 1992, The Australian and New Zealand journal of surgery.
[20] L. Norton. A Gompertzian model of human breast cancer growth. , 1988, Cancer research.
[21] I. Tannock,et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Bonadonna,et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.
[23] T. Nielsen,et al. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T J Yao,et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Singletary Se. New clinical trends in the adjuvant therapy of early stage breast cancer , 1998 .
[26] S. Singletary. New clinical trends in the adjuvant therapy of early stage breast cancer. , 1998, Acta oncologica.
[27] Skipper He. Laboratory models: some historical perspective. , 1986 .
[28] G. Bonadonna,et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Bonadonna,et al. Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.